Sorrento Therapeutics, Inc. Share Price Deutsche Boerse AG
Equities
8STN
US83587F2020
Biotechnology & Medical Research
Sales 2021 | 52.9M 48.55M 4.08B | Sales 2022 | 62.84M 57.66M 4.85B | Capitalization | 411M 378M 31.72B |
---|---|---|---|---|---|
Net income 2021 | -428M -393M -33B | Net income 2022 | -573M -526M -44.18B | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 111M 102M 8.54B | Net Debt 2022 | 84.53M 77.57M 6.52B | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | 949 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 31/12/88 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 02/03/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 31/03/12 |
David Lemus
BRD | Director/Board Member | 61 | 30/09/17 |
Jaisim Shah
BRD | Director/Board Member | 63 | 10/09/13 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |